Viyash Scientific further strengthens European Companion Animal Presence with acquisition of Italy's BioForLife

Viyash Scientific Limited (Viyash), through its wholly owned subsidiary Alivira Animal Health Limited (Alivira), has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. (BFL), a leading pet care company based in Milan, Italy. The acquisition, for a cash consideration of ~₹ 188 crore is expected to close in Q2 FY27. The transaction represents a significant step in Viyash's strategy to capitalize on the mega-trend of a growing Companion Animal Health Generics market. It expands Alivira's global Companion Animal Health business and strengthens its presence in the European pet care market.

Italy is among the five largest animal health markets in Europe, with companion animal care emerging as its fastest-growing segment driven by rising pet ownership, increasing pet humanization trends and higher spending on preventive and specialized veterinary care.

BioforLife, based in Milan, Italy, specializes in the development, commercialization and distribution of pet care products. With a strong product portfolio and pipeline for pet health, BFL has established strong positions in nutritional complements, pharmaceuticals, and rapid diagnostic tests. BFL is also building a business in fast growing segments like dermatology and ophthalmology. With a well-established front-end sales team, BFL reaches over 80% of all veterinary clinics in Italy, thereby providing well-established customer relationships for future growth.

The acquisition will provide a platform for launching new products from Alivira's pipeline in Italy, while simultaneously providing opportunities to expand the BFL range to other markets in the Alivira group located in Europe, Middle East, Asia and Latam.

Commenting on the acquisition, Dr. Haribabu Bodeputi, Managing Director and Group CEO, Viyash Scientific Limited, said: "This acquisition represents another important step in our strategy to build a leading global Companion Animal Health business. BioForLife provides us with an established platform in Italy, one of Europe's most attractive pet care markets, while strengthening our presence across the region. The combination of BioForLife's commercial reach and Alivira's product development capabilities creates a compelling opportunity to accelerate growth, expand our companion animal portfolio and deliver greater value to veterinarians, pet owners and partners across markets. We also see meaningful opportunities to introduce innovative products into India and other geographies through our global reach. This investment reflects our continued commitment to sustainable growth, strategic expansion and long-term value creation."

This transaction also strengthens the Alvira team with the induction of BFL executives who will continue to run the business operations, in addition to driving new growth initiatives.

This transaction further builds on Alvira's strong track record of global acquisitions, having successfully acquired and integrated animal health companies across Europe, Latam and Asia in the last 10 years.

Shares of Sequent Scientific Limited was last trading in BSE at Rs. 255.15 as compared to the previous close of Rs. 249.20. The total number of shares traded during the day was 867590 in over 8612 trades.

The stock hit an intraday high of Rs. 259.00 and intraday low of 248.45. The net turnover during the day was Rs. 221356333.00.

Source : Equity Bulls

Keywords

ViyashScientific SequentScientific INE807F01027 Pharmaceuticals Acquisition